Answers are grounded in this paper and cite their sources.
Upadacitinib (UPA) is an important selective Janus kinase 1 (JAK1) inhibitor used for the treatment of various chronic inflammatory diseases. However, the detailed crystal structures, systematic physicochemical studies, and phase transformation relationship of UPA solid forms were not reported. In this work, one hemihydrate, two anhydrous polymorphs, and an amorphous form of UPA were successfully prepared. The crystal structures of Forms I, II, and III were determined for the first time using single-crystal X-ray diffraction. Form I was identified as an isolated-site hydrate in which water molecules form strong hydrogen bonds with UPA molecules, playing a crucial role in structural stability. Form II and Form III are packing polymorphs with similar molecular conformations but distinct lattice arrangements. Furthermore, the key physicochemical properties of these UPA forms were evaluated, including thermal behavior, hygroscopicity, and solubility. The higher melting point and fusion enthalpy of Form II indicate a monotropic relationship between Forms II and III, with Form II being the thermodynamically stable polymorph and Form III being the metastable polymorph. Competitive slurry experiments further showed that Form II is favored in anhydrous acetonitrile, whereas Form I is favored under water-containing conditions. These findings highlight the critical role of hydration in UPA solid form stability and provide a rational basis for selecting the optimal form for pharmaceutical development.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: